About | JCO Oncology Advances - ASCO Publications
Scope. JCO Oncology Advances (JCO OA) is an online-only open-access journal dedicated to cutting-edge global clinical and translational research in the dynamic field of oncology.JCO OA strives to make global scientific advancements accessible to a broader audience, including clinicians, community oncologists, patients and patient advocacy groups.. About the Journal
KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in …
Background: Adagrasib (ADA) is a potent covalent inhibitor of KRAS G12C with favorable properties such as long half-life (23 h), dose-dependent pharmacokinetics, and brain penetrance. In the phase 1/2 KRYSTAL-1 trial, ADA demonstrated deep and durable responses with promising PFS and OS in patients (pts) with previously treated KRAS G12C-mutated NSCLC.. Here, we …
JCO Resource Center
The JCO Resource Center provides an opportunity to align your message with the world’s most authoritative and trusted content in clinical oncology.
Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) …
Jan 22, 2024 · Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study.
Phase 3 VERONA study of venetoclax with azacitidine to assess …
May 28, 2021 · Background: Patients with higher-risk myelodysplastic syndromes (HR-MDS) experience peripheral cytopenias, disease progression to acute myeloid leukemia, and high mortality with expected median overall survival of less than 2 years. Allogeneic hematopoietic cell transplantation (allo-HCT) is the only potentially curative treatment. Patients ineligible for …
ASCO Daily News
A post hoc assessment of patients with T1 to T3N0 rectal cancer enrolled on the phase 2 NEO trial found the Guardant Reveal tissue-free ctDNA assay effectively identifies cancers with inadequate response to chemotherapy for which total mesorectal excision (TME) was recommended (Abstract 20).
ASCO Clinical Practice Guidelines | Journal of Clinical Oncology
Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline May 17, 2024. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline January 5, 2023. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional …
Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with ...
May 29, 2024 · Background: TROP2 (trophoblast cell surface antigen 2) is highly expressed in TNBC and is associated with worse survival. Sacituzumab tirumotecan (SKB264/MK-2870) is a TROP2 ADC developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4.
Treatment and outcomes of goblet cell adenocarcinomas (GCAs) …
Jan 20, 2015 · Background: GCAs are rare mucinous neoplasms with mixed epithelial and endocrine differentiation, which behave more like mucinous adenocarcinomas than appendiceal neuroendocrine tumors. Optimal therapy is poorly described. Objectives of this study were to define prognostic factors and describe management of patients presenting with stage I-IV …
Low-Grade Prostate Cancer: Time to Stop Calling It Cancer
A common definition of cancer is a “malignant tumor (which) can invade and destroy adjacent structures and spread to distant sites,” 8 a view generally shared by the nonmedical public. 9 Although GS6 meets the pathologic criteria of a cancer (invasion of the stroma), without the simultaneous presence of higher-grade disease (GS ≥ 7; ie, Grade Group ≥ 2), it is effectively …